Literature DB >> 11420337

Detection of beta-lactamase-mediated resistance.

D M Livermore1, D F Brown.   

Abstract

beta-Lactams are the most widely used antibiotics, and beta-lactamases are the greatest source of resistance to them. An understanding of beta-lactamase detection and identification is therefore valuable. Colorimetric, acidimetric and iodometric tests of beta-lactamase production are good, rapid indicators of penicillin and ampicillin resistance in Haemophilus, Moraxella and Neisseria spp. These methods can also be applied to Gram-negative aerobic bacilli but are less useful, since the usual question is not whether a beta-lactamase is produced by these organisms, but which beta-lactamase? Accurate identification of the beta-lactamases of Enterobacteriaceae demands gene or protein sequencing, but the broad type of enzyme produced by an isolate can often be inferred from antibiotic susceptibility data. Resistance to ceftazidime or cefpodoxime implies extended-spectrum beta-lactamase (ESBL) production in Escherichia coli and Klebsiella spp., especially if susceptibility to cefoxitin is retained. ESBL production can be confirmed with double disc tests or with various commercial kits. Derepression of AmpC beta-lactamases in Enterobacter spp. and Citrobacter freundii is another important mechanism and can be inferred from cross-resistance to beta-lactamase inhibitor combinations and to all cephalosporins except fourth-generation agents. Antagonism between cefoxitin and cefotaxime can be used to infer the presence of inducible AmpC enzymes in these species, indicating the risk of segregation of derepressed mutants, but in general this risk is better predicted from accurate speciation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11420337     DOI: 10.1093/jac/48.suppl_1.59

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  65 in total

1.  Extended-spectrum beta-lactamase enzymes in clinical isolates of Enterobacter species from Lagos, Nigeria.

Authors:  I E Aibinu; V C Ohaegbulam; E A Adenipekun; F T Ogunsola; T O Odugbemi; B J Mee
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

2.  Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant Escherichia coli and Klebsiella spp.

Authors:  Maurine A Leverstein-van Hall; Ad C Fluit; Armand Paauw; Adrienne T A Box; Sylvain Brisse; Jan Verhoef
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

3.  High prevalence of extended-spectrum beta-lactamase-producing strains among blood isolates of Enterobacter spp. collected in a tertiary hospital during an 8-year period and their antimicrobial susceptibility patterns.

Authors:  Hyunjoo Pai; Jung Yun Hong; Jeong-Hum Byeon; Yun-Kyung Kim; Hoan-Jong Lee
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

4.  CTX-M1 ESBL-producing Klebsiella pneumoniae subsp. pneumoniae isolated from cases of bovine mastitis.

Authors:  Clara Locatelli; Licia Scaccabarozzi; Giuliano Pisoni; Paolo Moroni
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

5.  Resistant plasmid profile analysis of multidrug resistant Escherichia coli isolated from urinary tract infections in Abeokuta, Nigeria.

Authors:  O Akingbade; S Balogun; D Ojo; P Akinduti; P O Okerentugba; J C Nwanze; I O Okonko
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

6.  Screening for extended-spectrum beta-lactamase-producing pathogenic enterobacteria in district general hospitals.

Authors:  Nteimam Jonathan
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

7.  Detection of a bla(SHV) extended-spectrum {beta}-lactamase in Salmonella enterica serovar Newport MDR-AmpC.

Authors:  Shelley C Rankin; Jean M Whichard; Kevin Joyce; Lynn Stephens; Kathleen O'shea; Helen Aceto; Donald S Munro; Charles E Benson
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

8.  Evaluation of the current National Committee for Clinical Laboratory Standards guidelines for screening and confirming extended-spectrum beta-lactamase production in isolates of Escherichia coli and Klebsiella species from bacteremic patients.

Authors:  O T Katz; N Peled; P Yagupsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10-08       Impact factor: 3.267

Review 9.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae.

Authors:  Hyunjoo Pai; Cheol-In Kang; Jeong-Hum Byeon; Ki-Deok Lee; Wan Beom Park; Hong-Bin Kim; Eui-Chong Kim; Myoung-Don Oh; Kang-Won Choe
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.